Sharechat Logo

Ebos shareholders approve $1.1 billion purchase of Symbion

Friday 14th June 2013

Text too small?

Ebos Group shareholders approved the company's $1.1 billion purchase of the Symbion pharmaceutical wholesaler and distributer in Australia.

All six resolutions were passed at the meeting in Christchurch, paving the way for Ebos to triple annual sales to more than $6 billion as it looks to become Australasia's biggest pharmaceutical wholesaler and distributor.

"The increased scale and complementary nature of both businesses is expected to open up additional revenue opportunities and operational efficiencies," managing director Mark Waller said.

As part of the purchase, the company aims to raise $149 million from existing shareholders through a pro-rata rights issue. Two directors from Symbion parent Zuellig will join the Ebos board.

Shares in Christchurch-based Ebos dropped 0.2 percent to $9.53, having gained 32 percent this year.

BusinessDesk.co.nz

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos funding line smaller than previously flagged at $135 mln
Ebos Group
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions
Daily ShareChat: EBOS Group

IRG See IRG research reports